Akili Interactive Labs, Inc.

43 articles with Akili Interactive Labs, Inc.

• Akili to Participate in the Cowen 43rd Annual Health Care Conference

  2/2/2023

  Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Cowen 43rd Annual Health Care Conference in Boston next month.

• Shionogi Begins Phase 3 Study in Japan of Akili’s Digital Treatment in Children with ADHD

  8/1/2022

  Akili Interactive (“Akili”), a leading digital medicine company, today announced the start of a pivotal Phase 3 randomized, controlled study of SDT-001 (a version of AKL-T01 localized for Japanese language and culture), a product candidate designed to improve measures of attention in children diagnosed with attention-deficit/hyperactivity disorder (“ADHD”).

• The Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of Akili’s AKL-T01 Product Candidate

  7/14/2022

  Akili Interactive Labs, Inc., a leading digital medicine company, announced the publication of full data from a randomized, unblinded study conducted by National Jewish Health and the University of Colorado School of Medicine Departments of Neurology, Psychiatry and Rheumatology that evaluated the ability of Akili’s digital therapeutic AKL-T01 to improve cognitive dysfunction in patients diagnosed with Systemic Lupus Erythematosus.

• PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

  7/11/2022

  New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS.

• The American Journal of Psychiatry Publishes Data Demonstrating Akili Interactive’s Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults with Major Depressive Disorder When Combined with Antidepressant Medication

  4/12/2022

  The American Journal of Psychiatry Publishes Data Demonstrating Akili Interactive’s Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults with Major Depressive Disorder When Combined with Antidepressant Medication.

• Akili to Present at Chardan’s Prescription Digital Therapeutics Half-Day Summit

  4/4/2022

  Akili Interactive today announced that management will present at Chardan’s Prescription Digital Therapeutics Half-Day Summit on Monday, April 11, 2022 at 2:00 p.m. E.T.

• 

  BioSpace Movers & Shakers, March 25

  3/25/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Akili to Speak at SXSW 2022 on Building a New Class of Disease-Modifying Digital Therapeutics

  3/10/2022

  Akili Interactive announced that co-founder and Chief Executive Officer, Eddie Martucci, will participate in a panel discussion at SXSW 2022, a conference that convenes a global community of digital creatives with a shared pursuit of forward-thinking, cutting-edge ideas.

• PureTech Founded Entity Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022

  3/8/2022

  PureTech Founded Entity Akili Named to Fast Company ’s Annual List of the World’s 50 Most Innovative Companies for 2022.

• Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022

  3/8/2022

  Akili Interactive Labs, Inc., a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, announced it has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies for 2022.

• Akili to Present at Cowen’s 42nd Annual Health Care Conference

  3/7/2022

  Akili Interactive today announced that management will present at Cowen’s 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. E.T.

• Akili to Speak on Integrating Digital Therapeutics Into Mainstream Healthcare at DTx West 2022

  2/18/2022

  Akili Interactive today announced that Chief Financial Officer, Santosh Shanbhag, and Vice President of Marketing, Blake Schiller, will each participate in panel discussions at the fifth annual DTx West event.

• PLOS ONE Publishes Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning

  2/17/2022

  PLOS ONE Publishes Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx ® Activates Systems in Brain Key to Attentional Functioning.

• Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I

  2/14/2022

  Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I.

• PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

  1/26/2022

  PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

• Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

  1/26/2022

  Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp.

• PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatment for Patients with COVID Brain Fog

  4/7/2021

  PureTech Health plc is pleased to note that its Founded Entity, Akili Interactive announced collaborations with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to evaluate Akili digital therapeutic AKL-T01 as a treatment for patients with cognitive dysfunction following COVID-19.

• Akili Announces CE Mark Approval of EndeavorRxTM Digital Treatment for Children With ADHD

  6/23/2020

  Delivered through a video game experience, EndeavorRx has been studied across five clinical studies including a large, randomized controlled trial

• 

  FDA Approves Akili’s Therapeutic Video Game for ADHD

  6/16/2020

  The game was reviewed through the agency’s de novo pathway and as a result, creates a new class of digital therapeutics.

• Akili Announces FDA Clearance of EndeavorRxTM for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game

  6/15/2020

  Shown to improve attention function, EndeavorRx is backed by data from five clinical studies, including a prospective, randomized controlled trial